J.M. Cecka
University of California, Los Angeles
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.M. Cecka.
Clinical Journal of The American Society of Nephrology | 2008
Jagbir Gill; Madhira Br; David W. Gjertson; Gerald S. Lipshutz; J.M. Cecka; Phuong-Thu T. Pham; Alan H. Wilkinson; Suphamai Bunnapradist; Gabriel M. Danovitch
BACKGROUND AND OBJECTIVESnTransplant tourism typically refers to the practice of traveling outside the country of residence to obtain organ transplantation. This study describes the characteristics and outcomes of 33 kidney transplant recipients who traveled abroad for transplant and returned to University of California, Los Angeles (UCLA) for follow-up.nnnDESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTSnPosttransplantation outcomes were compared between tourists and a matched cohort of patients who underwent transplantation at UCLA (matched for age, race, transplant year, dialysis time, previous transplantation, and donor type). Median follow-up time was 487 d (range 68 to 3056).nnnRESULTSnCompared with all patients who underwent transplantation at UCLA, tourists included more Asians and had shorter dialysis times. Most patients traveled to their region of ethnicity with the majority undergoing transplantation in China (44%), Iran (16%), and the Philippines (13%). Living unrelated transplants were most common. Tourists presented to UCLA a median of 35 d after transplantation. Four patients required urgent hospitalization, three of whom lost their grafts. Seventeen (52%) patients had infections, with nine requiring hospitalization. One patient lost her graft and subsequently died from complications related to donor-contracted hepatitis B. One-year graft survival was 89% for tourists and 98% for the matched UCLA cohort (P = 0.75). The rate of acute rejection at 1 yr was 30% in tourists and 12% in the matched cohort.nnnCONCLUSIONSnTourists had a more complex posttransplantation course with a higher incidence of acute rejection and severe infectious complications.
Kidney International | 2013
Jeremy M. Blumberg; Gritsch Ha; Elaine F. Reed; J.M. Cecka; Gerald S. Lipshutz; Gabriel M. Danovitch; S. McGuire; David W. Gjertson; Jeffrey Veale
Incompatible donor/recipient pairs with broadly sensitized recipients have difficulty finding a crossmatch-compatible match, despite a large kidney paired donation pool. One approach to this problem is to combine kidney paired donation with lower-risk crossmatch-incompatible transplantation with intravenous immunoglobulin. Whether this strategy is non-inferior compared with transplantation of sensitized patients without donor-specific antibody (DSA) is unknown. Here we used a protocol including a virtual crossmatch to identify acceptable crossmatch-incompatible donors and the administration of intravenous immunoglobulin to transplant 12 HLA-sensitized patients (median calculated panel reactive antibody 98%) with allografts from our kidney paired donation program. This group constituted the DSA(+) kidney paired donation group. We compared rates of rejection and survival between the DSA(+) kidney paired donation group with a similar group of 10 highly sensitized patients (median calculated panel reactive antibody 85%) that underwent DSA(-) kidney paired donation transplantation without intravenous immunoglobulin. At median follow-up of 22 months, the DSA(+) kidney paired donation group had patient and graft survival of 100%. Three patients in the DSA(+) kidney paired donation group experienced antibody-mediated rejection. Patient and graft survival in the DSA(-) kidney paired donation recipients was 100% at median follow-up of 18 months. No rejection occurred in the DSA(-) kidney paired donation group. Thus, our study provides a clinical framework through which kidney paired donation can be performed with acceptable outcomes across a crossmatch-incompatible transplant.
The Journal of Urology | 1998
Y.W. Cho; Paul I. Terasaki; J.M. Cecka; David W. Gjertson
BACKGROUNDnAttempts have recently been made to expand the number of cadaveric kidneys available for transplantation by using kidneys from donors without heartbeats in addition to those from brain-dead donors with beating hearts. We studied the efficacy of transplanting kidneys from donors without heartbeats on the basis of aggregate results from the Kidney Transplant Registry of the United Network for Organ Sharing.nnnMETHODSnWe compared the early function and survival rates of 229 kidney grafts from donors without heartbeats with those of 8718 grafts from cadaveric donors with heartbeats. All transplantations were performed at 64 U.S. transplantation centers. Cox proportional-hazards analysis was used to evaluate 10 major risk factors for graft failure.nnnRESULTSnThe survival rate at one year was 83 percent for kidney grafts from donors without heartbeats, as compared with 86 percent for grafts from donors with heartbeats (P=0.26). Among the kidneys from donors without heartbeats, the survival rate at one year was 89 percent for grafts from donors who had died of trauma, as compared with 78 percent for grafts from donors who had died of other causes (P=0.04). The survival rates were high for grafts from donors without heartbeats despite the poorer early function of these grafts; 48 percent of the recipients required dialysis within the first week after transplantation, as compared with 22 percent of the recipients of grafts from donors with heartbeats. The primary-failure rate for kidneys from donors without heartbeats was 4 percent, as compared with 1 percent for kidneys from donors with heartbeats.nnnCONCLUSIONSnTransplantation of kidneys from donors whose hearts have stopped beating, especially those who have died of trauma, is often successful, and the use of kidneys from such donors could increase the overall supply of cadaveric kidney transplants.
American Journal of Transplantation | 2016
J.M. Cecka; David W. Gjertson; Elaine F. Reed
Paul Terasaki was a pioneer of transplantation and had a global following. His career, which spanned >50 years, included accomplishments and discoveries that revolutionized the field of transplantation and that advanced the care of transplant patients. Paul is survived by his wife Hisako, his brother, four children and six grandchildren as well as legions of close friends and colleagues around the world who will continue to build on his successes.
Transplantation Proceedings | 1999
J.M. Cecka
Transplantation Proceedings | 1997
J.M. Cecka; Paul I. Terasaki
Transplantation Proceedings | 1998
Y.W. Cho; Paul I. Terasaki; J.M. Cecka
Transplantation Proceedings | 2001
David W. Gjertson; J.M. Cecka
Transplantation Proceedings | 2001
Steven K. Takemoto; Ben Bradley; David W. Gjertson; Y.W. Cho; J.M. Cecka
Transplantation | 2000
Suphamai Bunnapradist; Yong W. Cho; Alan H. Wilkinson; Gabriel M. Danovitch; J.M. Cecka